Towards Healthcare
AI in Cardiology Market Size Leads 34.38% CAGR by 2034

AI in Cardiology Market Trends, Advances & Deep Learning in Echocardiography

Forecasts suggest that the AI in cardiology market will expand from USD 1.91 billion in 2024 to USD 36.64 billion by 2034, with a CAGR of 34.38% during this period. AI in cardiology refers to the use of artificial intelligence to analyze heart-related data, assist in diagnosing conditions, predict risks, and improve treatments. It helps doctors detect heart diseases early, interpret ECGs and imaging, and personalize patient care, making heart healthcare faster, more accurate, and efficient.

AI in Cardiology Market Size, Remote Monitoring Care & Era of Precision Medicine

The global AI in cardiology market size is expected to increase from USD 2.56 billion in 2025 to USD 36.64 billion by 2034, growing at a CAGR of 34.38% throughout the forecast period from 2025 to 2034, as a result of the rising prevalence of cardiovascular disorders and improve technological advancements.

AI in Cardiology Market Size 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Accelerated Detection in Cardiology, Facilitated by AI Advancement, is Contributing to the Market Growth.

Key Takeaways

  • North America dominated the global market in 2024.
  • Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
  • By component, the hardware segment held a dominant presence in the market in 2024.
  • By component, the software segment is anticipated to grow with the highest CAGR in the market during the studied years.
  • By application, the diagnosis segment held the largest share of the market in 2024.
  • By application, the prediction segment is projected to expand rapidly in the market in the coming years.
  • By medical condition, the ischemic heart disease/CAD segment led the global market in 2024.
  • By medical condition, the cardiac arrhythmias segment is expected to grow at the fastest rate in the market during the forecast period.

AI in Cardiology Market Overview

According to the World Health Organization, Heart attacks and strokes account for 85% of deaths worldwide, and cardiovascular diseases (CVDs) account for 17.9 million deaths annually, making up 31% of all deaths. Artificial intelligence helps identify cardiovascular diseases more quickly using ECGs, imaging, biomarker tracing, and atrial fibrillation assessment. This contributes significantly to the successful diagnosis and treatment of cardiovascular diseases. By helping with risk assessment, medication discovery, treatment planning, and medical diagnosis, this technology has tremendous potential to completely transform the healthcare industry.

Artificial Intelligence (AI) is the ability to instruct a computer how to solve a problem. AI is helpful because it allows computers to gather information from data and make well-informed decisions. Through machine learning and deep learning techniques, researchers have developed several systems that greatly enhance the detection of cardiovascular diseases, ultimately resulting in more accurate and efficient diagnoses. As AI proliferates, it is anticipated to benefit patients, cardiologists, healthcare providers, insurance companies, and international policymakers.

Artificial intelligence utilization includes effectively analyzing vast amounts of data and dealing with tricky medical problems. The advancement of Al techniques demonstrates the potential of Al in future cardiology for precise assessment of CVD results, non-invasive diagnosis of coronary artery disease (CAD), detection of arrhythmias through wearables, diagnosis, treatment strategies, and outcome prediction for patients with heart failure (HF). With the development of artificial intelligence (AI), the Internet of Things (IoT), and precision medicine.

Applications of AI in the department of Cardiology are given below

Application of AI in Cardiology

The global market for AI in cardiology is also growing quickly. Not only is the insertion of AI tools into cardiovascular medicine services, but it also opens up new avenues for improved patient care, streamlined procedures, and scientific advances. Accepting the potential of artificial intelligence (AI) is crucial to achieving its full impact on cardiovascular healthcare as we advance. Cutting-edge digital technologies will play a significant role in the field of cardiology in the future.

  • In February 2025, Cardio Diagnostics Holdings, Inc. announced the company partnered with seven new provider organizations to enhance the reach of its AI-driven precision cardiovascular medicine tests, such as Epi+Gen CHD and PrecisionCHD. This enables the company to transform the prevention, detection, and management of coronary heart disease.
  • In July 2024, Octagos Health announced that it raised $43 million in a Series B funding round to use AI to revolutionize cardiac care and provide comprehensive patient monitoring services. The company offers Atlas AI, a proprietary technology, for continuous monitoring and data analysis for patients with cardiac devices.
  • In June 2024, Anumana announced a strategic collaboration with InfoBionic.Ai to develop and commercialize the next generation of remote cardiac care solutions. The collaboration was made to combine Anumana’s ECG-AI technology and InfoBionic.Ai’s MoMe ARC platform.

Spotlight of AI in cardiology

  • Artificial intelligence focuses on the challenges of creating things that decide in given circumstances.
  • The medical field of cardiology is leading the way in the Artificial intelligence revolution.
  • Al enables precise cardiovascular outcome prediction, non-invasive coronary artery disease diagnosis, identification of arrhythmias, stroke and diagnosis, management, and outcome prediction for heart failure patients.
  • The Internet of Things, artificial intelligence, and precision medicine will influence future developments in cardiovascular research.
  • Unresolved ethical and data privacy issues constrain Cardiology's use of artificial intelligence.
  • Regulations must be implemented for the safe application of artificial intelligence in cardiology and medicine.

Global Market Expands Due to AI Revolution in Cardiology

Global Market Expands Due to AI Revolution in Cardiology: This could be the Next Big Thing in Cardiovascular Medicine Sciences. The limitations of the instruments and practices used in clinical medicine today should serve as a stimulus for the growing use of Al tools in patient care. This field of innovation will expand rapidly, and many large corporations are investing in Al health care start-ups. Al is a participant in the digital revolution that is taking place in every sector of the economy. The accessibility of increasing digital data sourced from EHR and rapid advancements in computers and the web have created ideal conditions for the growth of Al.

For Instance,

  • One application of Al is monitoring atrial fibrillation in the general population with a commercially available wristwatch sensor; the results were similar to those of the study involving the conventional insertable cardiac monitor arm. Al's technological advancements include the wireless navigation of robotic EP systems for cardiac arrhythmia catheter ablation. This lessens operator fatigue and enables the doctor to manage the catheter navigation from a comfortable, radiation-free location.

Al will continue to play a significant role in many areas of cardiovascular care in the near future, including cardiac imaging, developing algorithms from large databases traced with general guidelines, and predicting risk scores and outcomes. Significant clinical and financial benefits would result from innovative Al approaches in cardiology, which would aid in providing quick, accurate, and less inaccurate patient care. Physicians shouldn't be afraid to embrace Al to improve workflow dynamics; Al technology won't replace them.

The most popular Al application at the moment is automated medical image classification. Research has shown that Al can match or surpass human experts in various image-based medical specializations, such as radiology, where a network of convolutional neural networks trained with labelled frontal chest X-rays performed better than radiologists. Cardiology's deep learning algorithm identified a heart attack with accuracy on the same level as cardiologists' work.

FDA-Approved AL/ML-based Technologies for Assessment of Cardiovascular Diseases:

Approval Date Device Name Parent Company Name Description FDA Approval Number
March, 2020 AI ECG Tracker Shenzen Carewell Electronics Detection of Arrythmias using ECG data aquired from adult without pacemaker K200036
October, 2020 ECG 2.0 App Apple Inc. Rhythm assessment Ambulatory ECG K201525
April, 2021 Gili Biosenser System Continuse Biometrics Hardware and Software for Optical Camera based measurement of pulse rate, heart rate, and/or breathing rate DEN200038
June, 2021 LINQ II Insertable Cardiac Monitor, Zelda AI ECG Classification System Medtronic Inc. Assessment of Arrythmia and alarm (Including ST segment measurement and alarm) K210484
June, 2022 Atrial fibrillation history feature Apple Inc. Assessment of Atrial fibrillation K213971


Due to this innovation, patients will receive care more quickly and accurately, and physicians can use Artificial Intelligence to enhance their practice without fear of being replaced. Regarding the future of heart health, the development of AI is significant.

The Rising Prevalence of Cardiovascular Diseases Drives the Market for AI in Cardiology

An estimated 1.28 billion adults globally aged 30-79, suffer from hypertension; the majority of these individuals, or two-thirds, reside in low- and middle-income nations. It's estimated that 46% of adults with hypertension are ignorant of their illness. Only 42% of adult patients with hypertension receive a diagnosis and course of treatment. One in five adults (21%) who have hypertension can control it. Globally, one of the leading causes of premature death is hypertension. Heart attacks and strokes cause 85% of deaths.

Coronary Heart Disease Death Rates by Age and Sex, 2021

The demand for artificial intelligence (AI) has surged globally due to the rise in CAD across the globe. The need for cutting-edge technology to support diagnosis, treatment, and overall patient care has increased as heart-related problems become more common. AI provides valuable tools for managing cardiovascular health, including risk prediction, image interpretation, and decision support. Globally, cardiovascular diseases remain the primary cause of morbidity and death, encompassing Arrhythmia, stroke, and other associated conditions.  These diseases are becoming more common, which has increased the demand for cutting-edge technologies like artificial intelligence to improve early detection, diagnosis, and individualized treatment.

For Instance,

  • For example, a study published in the Journal of the American College of Cardiology predicted that in 2060, the prevalence of cardiovascular disease and risk factors in the US would have increased significantly. Ischemic heart disease has the most significant predicted increases in rates between 2025 and 2060 among the general U.S. population, followed by heart attack and stroke, according to the researchers. All cardiovascular risk factors are expected to rise during this time. Consequently, the facts listed above support the market expansion during the forecast period.

This surge in demand reflects a recognition of AI's potential to enhance the efficiency and effectiveness of cardiovascular care, addressing the challenges posed by the growing burden of heart-related conditions on healthcare systems globally.

Safety Concerns and Inappropriate Use of AI Decreased the Global Cardiology Market

When using biomedical AI tools, there are significant concerns about diagnosing potentially fatal conditions and the potential for inaccurate evaluations. The effectiveness of these tools, even in cases where they are accurate, depends on how people (physicians, other healthcare workers, and patients) use them. Inadequate use can result in better scheduling, more treatment, and effective interventions.

The wide availability of online and mobile AI solutions without appropriate and the general public, the lack of training provided to healthcare professionals on medical AI, and the minimal involvement of medical professionals and citizens in AI development all contribute to the inappropriate use of AI in healthcare. The impact of sizable datasets that may produce erroneous results exacerbates the misuse. Combining these factors prevents The cardiology market from adopting AI widely.

Al has numerous advantages, but there are also security and privacy concerns that need to be taken into account. The potential for hacking of data is one of the main hazards. Large volumes of highly confidential patient data are created, received, stored, and transmitted by healthcare providers. They become targets for online fraudsters and data security and privacy issues present challenges for the AI cardiology market. Combining these factors prevents The cardiology market from adopting AI widely.

Segmental Insights

Hardware Segment Dominated

By component, the hardware segment held a dominant presence in the market in 2024. Some common examples of AI hardware include wearable devices and AI-assisted medical imaging tools. It also includes patches and vests equipped with sensors. These devices enable real-time monitoring of patient vital signs such as blood pressure, heart rate, and respiration rate. Technological advancements and the availability of affordable devices boost the segment’s growth. Healthcare professionals can monitor a patient from remote places. Hardware can also improve the efficiency of disease detection non-invasively.

Software Segment: Fastest-Growing

By component, the software segment is anticipated to grow with the highest CAGR in the market during the studied years. The software enables diagnosing patient conditions through mobile apps. It also helps healthcare providers and patients to store large amounts of patient data and access it anywhere and at any time. The advent of cloud computing boosts the segment’s growth. The software eliminates the need for the availability of favorable infrastructure to install huge devices. AI-enabled software accelerates the progression of diagnosis and treatment of CVDs.

The Diagnosis Segment Held the Largest Share

By application, the diagnosis segment held the largest share of the market in 2024. Machine learning (ML) and deep learning (DL) algorithms are predominantly used to diagnose cardiovascular disorders in patients. They can identify coronary atherosclerotic plaques more accurately than clinicians. They can also analyze medical imaging data and detect the presence of potential diseases that are undetectable by human observation. ML and DL can also identify different disease stages. Several government organizations have imposed guidelines for the early detection of cardiovascular disorders, reducing the burden on healthcare systems. All these factors are responsible for propelling the segment’s growth.

Prediction Segment: Fastest-Growing

By application, the prediction segment is projected to expand rapidly in the market in the coming years. The predictive models enable healthcare professionals to predict disease outcomes in high-risk individuals. AI can analyze potential biomarkers through various diagnostic tests. According to a study published in the American Heart Association Journal, AI/ML predicted cardiac arrest up to 50 minutes before onset in 91% of patients in the pediatric ICU, compared with only 6% by clinicians.

Ischemic Heart Disease/CAD Segment Led in 2024

By medical condition, the ischemic heart disease/CAD segment led the global market in 2024. The rising prevalence of ischemic heart disease and coronary artery disease, as well as their complexities, boost the segment’s growth. It is estimated that by 2050, the global incidence and prevalence rate of IHD will reach 67.3 million and 510 million, respectively. AI plays a vital role in identifying subtle patterns and correlations, interpreting ECGs, and stratifying patients based on their risk of developing IHD/CAD. It can also be integrated with electronic health records (EHR), enhancing diagnostic accuracy.

Cardiac Arrhythmias Segment: Fastest-Growing

By medical condition, the cardiac arrhythmias segment is expected to grow at the fastest rate in the market during the forecast period. Atrial fibrillation is a type of cardiac arrhythmia affecting 1.5-2% of European adults. The increasing incidence of cardiac arrhythmias potentiate the segment’s growth. AI is used to improve the detection and diagnosis of cardiac arrhythmias by analyzing medical imaging data.

For instance,

  • In October 2023, researchers from Smidt Heart Institute at Cedars-Sinai developed an AI algorithm to detect an abnormal heart rhythm in people not yet showing symptoms. This algorithm identified hidden signals in common medical diagnostic testing, enabling doctors to prevent strokes and other cardiovascular complications.

Geographical Landscape

Coronary artery disease (CAD) is the most common type of heart disease in the U.S., according to the Centers for Disease Control and Prevention (CDC). Heart disease-related medical costs are predicted to soar in the United States, from $126.2 billion in 2010 to $177.5 billion in 2040, a 41% increase. A robust healthcare system, the quick uptake of cutting-edge products, and the region's growing number of new artificial intelligence (AI) product approvals by regulators are some of the factors driving this upward trend.

Innovation and Collaboration

  • In September 2023, ACC collaborated with Serv Medical, a Singapore-based big healthcare data and AI company, to innovate cardiovascular care through digital therapeutics and increase medical experience in the developing market. 
  • November 2023, Synergy between HeartSciences collaborate with Icanh School of Medicine. Their collaboration aims to revolutionize ECG analysis, making HeartSciences a key player in heart diagnostics.

Asia-Pacific is projected to expand rapidly in the market in the coming years. The crude prevalence of CVDs is estimated to reach 729.5 million in Asia, a 109% increase from 2025. It is anticipated that the region's prevalence of cardiovascular disease (CVD) will rise sharply due to factors like an aging population, growing healthcare facilities, and an increase in the incidence of cardiovascular illnesses. For example, the Asian Development Bank projects that by 2050, one in four people in Asia and the Pacific will be over 60, or approximately 1.3 billion seniors—a fourfold increase in the population between 2010 and 2050.

Latest Announcement by Industry Leaders

Dr. Atul Gupta, Chief Medical Officer of Diagnosis and Treatment at Philips, commented that cardiology leaders are quickly realizing the potential of AI, with 40% saying their organizations plan to invest in generative AI in 12 months. He also said that by leveraging AI across their advanced technology portfolios, the company’s integrated solutions can help solve cardiology’s daily challenges.

Recent Developments

  • In February 2023, Cardio Diagnosis Holdings announced the launch of PrecisionCHD. An integrated genetic-epigenetic blood test is the recently launched platform for the early detection of coronary heart disease. According to the company, This is the second clinical trial in which AI is used.
  • In January 2025, researchers from Yale School of Medicine’s Cardiovascular Data Science (CasDS) Lab developed an AI tool to identify individuals at high risk of developing heart failure using ECG images. The tool enables earlier identification of heart failure, reducing hospitalizations and premature death.

AI in Cardiology Market Companies

AI in Cardiology Market Companies

AI in Cardiology Market Segments

By Component

  • Hardware
  • Software
  • Services

By Application

  • Diagnosis
  • Prediction
  • Drug Discovery
  • Others

By Medical Condition

  • Ischemic Heart Disease/CAD
  • Cardiac Arrhythmias
  • Heart Failure
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5077
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Last Updated: 06 March 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Rohan Patil is a market research expert with 5+ years of experience in healthcare, specializing in market dynamics, emerging trends, and technology-driven innovations to guide data-driven decisions for healthcare organizations.

Learn more about Rohan Patil

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The rising prevalence of cardiovascular diseases, including CAD, IHD, and strokes, has indeed led to an increased demand for AI detection methods in cardiology, driving market growth. AI technologies offer promising advancements in early diagnosis and personalized treatment planning for cardiovascular conditions. Continuous advancements in machine learning algorithms, data analytics, and imaging technologies contribute to more accurate and efficient cardiovascular disease detection and management. This innovation-driven progress enhances the overall effectiveness of AI applications in cardiology.

The North America dominate globally is expected to see a 41 percent increase in heart disease related medical costs between 2010 and 2040, from USD 126.2 billion to USD 177.5 billion. Some of the factors driving this upward trend include the regions expanding number of new artificial intelligence product approvals by regulators, a strong healthcare system and the rapid adoption of cutting edge products.

Key market players, including Philips, Siemens Healthineers, Medtronic, Johnson & Johnson, Google Health, Microsoft Healthcare, Ultromics Limited, CardiAl, IBM Watson Health, and IDOVEN, are key market players contributing significantly to the growth of AI in cardiology. Their research, development, and integration of AI technologies in diagnostic tools and healthcare systems play a pivotal role in advancing cardiological practices.

World Health Organisation, Food and Drug Administration, National Institute of Health, European Parliamentary Research Service, American College of Cardiology Foundation, British Heart Foundation, Center for Disease Control and Prevension.